OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Safety is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	119
Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt	99
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	86
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	79
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies	50
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	45
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	44
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	42
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	35
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	32
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	32
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	29
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	28
The role of artificial intelligence in pharmacovigilance for rare diseases	27
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	27
The safety of phthalate-containing medications used during pregnancy	26
Why is pharmacovigilance essential for biosimilars?	26
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	25
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	23
Long-term safety of ketamine and esketamine in treatment of depression	22
An updated safety review of Hidradenitis Suppurativa treatment options	21